<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04670796</url>
  </required_header>
  <id_info>
    <org_study_id>HLX02-HV02</org_study_id>
    <nct_id>NCT04670796</nct_id>
  </id_info>
  <brief_title>A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects</brief_title>
  <official_title>A Phase I Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity Between HLX02 and Herceptin® (US-licensed and EU-approved Reference Products, Double-blind, Randomized, Parallel-group Part) in Healthy Chinese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomised, double-blind, parallel group Phase I study to compare PK profiles and to assess&#xD;
      the safety and immunogenicity between HLX02 and Herceptin® (U.S. and EU).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>57 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>57 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to Cmax (Tmax)</measure>
    <time_frame>57 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>HLX02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient receive one dose of HLX02</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-sourced Trastuzumab (Herceptin®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient receive one dose of EU-sourced Trastuzumab (Herceptin®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-licensed Trastuzumab (Herceptin®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patient receive one dose of US-licensed Trastuzumab (Herceptin®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX02</intervention_name>
    <description>subject receive one dose of HLX02</description>
    <arm_group_label>HLX02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU-sourced Trastuzumab (Herceptin®)</intervention_name>
    <description>subject receive one dose of EU-sourced Trastuzumab (Herceptin®)</description>
    <arm_group_label>EU-sourced Trastuzumab (Herceptin®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US-licensed Trastuzumab (Herceptin®)</intervention_name>
    <description>subject receive one dose of US-licensed Trastuzumab (Herceptin®)</description>
    <arm_group_label>US-licensed Trastuzumab (Herceptin®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily signed Informed Consent Form&#xD;
&#xD;
          2. Healthy Chinese male (healthy is defined as the fact that no clinically significant&#xD;
             abnormalities are identified by medical history, physical examination, vital signs,&#xD;
             chest X ray, 12-lead ECG and laboratory tests)&#xD;
&#xD;
          3. Aged ≥ 18 and ≤ 45 years&#xD;
&#xD;
          4. Body mass index (BMI) ≥ 19 and ≤ 28 kg/m2&#xD;
&#xD;
          5. Body weight ≥ 50 and ≤ 80 kg&#xD;
&#xD;
          6. LVEF within normal range as examined through echocardiogram within 14 days prior to&#xD;
             randomization (&gt;50%)&#xD;
&#xD;
          7. Immunogenicity (anti-drug [anti-trastuzumab] antibody [ADA]) tested as negative&#xD;
&#xD;
          8. Subject agrees that he and his female spouse/partner use reliable contraceptive&#xD;
             methods from the time of administration of study drug until 3 months after the end of&#xD;
             study, or subject is infertile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically serious disease history or allergic disease, such as hematologic,&#xD;
             renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, mental and&#xD;
             nervous diseases and tumor&#xD;
&#xD;
          2. Use of monoclonal antibodies or any biological agent within 6 months prior to the&#xD;
             administration of the study drug&#xD;
&#xD;
          3. History of allergic reactions, including allergic reactions caused by any drug or&#xD;
             excipient in clinical study&#xD;
&#xD;
          4. Use of any prescription or non-prescription drug or dietary supplement within 5 half&#xD;
             lives of such drug or dietary supplement or 2 weeks prior to the administration of the&#xD;
             study drug (whichever is longer). The traditional Chinese medicine-based dietary&#xD;
             supplement should be discontinued 28 days prior to administration of the study drug&#xD;
&#xD;
          5. Donation of blood within 3 months prior to the administration of the study drug&#xD;
&#xD;
          6. Participation in other clinical studies within 3 months prior to the administration of&#xD;
             the study drug&#xD;
&#xD;
          7. Positive test result(s) for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
             (HCV) antibody, human immunodeficiency virus (HIV) antibody and treponema pallidum&#xD;
&#xD;
          8. History of drug abuse&#xD;
&#xD;
          9. Inability to follow the protocol requirements, instructions and study limitations as&#xD;
             judged by investigators, such as noncooperation, inability to return to the site for&#xD;
             follow-up visits or inability to complete the whole clinical study&#xD;
&#xD;
         10. Subject confirmed SARS-CoV-2 infection by appropriate test (including but not limited&#xD;
             to nucleic acid test) in screening period&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yue Li</last_name>
    <phone>021-33395800*6034</phone>
    <email>Black_Li@henlius.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quanying zhang</last_name>
      <phone>+86-512-68282030</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

